These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 15585625)

  • 21. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis.
    Umetani N; Takeuchi H; Fujimoto A; Shinozaki M; Bilchik AJ; Hoon DS
    Clin Cancer Res; 2004 Nov; 10(22):7475-83. PubMed ID: 15569977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
    Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
    Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
    Suzuki M; Iizasa T; Nakajima T; Kubo R; Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
    Ann Surg Oncol; 2007 Sep; 14(9):2636-42. PubMed ID: 17602269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
    Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
    Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
    Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
    Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
    Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
    Virmani AK; Tsou JA; Siegmund KD; Shen LY; Long TI; Laird PW; Gazdar AF; Laird-Offringa IA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):291-7. PubMed ID: 11895880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.